Search

Author/Creator Musolino, A

1. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. (17th January 2019)

Authors:
Dieci, M V; Conte, P; Bisagni, G; Brandes, A A; Frassoldati, A; Cavanna, L; Musolino, A; Giotta, F; Rimanti, A; Garrone, O; Bertone, E; Cagossi, K; Sarti, S; Ferro, A; Piacentini, F; Maiorana, A; Orvieto, E; Sanders, M; Miglietta, F; Balduzzi, S
Journal:
Annals of oncology
Issue:
Volume 30:Number 3(2019)
Page Start:
418
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. (13th September 2018)

Authors:
Conte, P; Frassoldati, A; Bisagni, G; Brandes, A A; Donadio, M; Garrone, O; Piacentini, F; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Molino, A; Musolino, A; Ferro, A; Maltoni, R; Danese, S; Zamagni, C; Rimanti, A; Cagossi, K; Russo, A
Journal:
Annals of oncology
Issue:
Volume 29:Number 12(2018)
Page Start:
2328
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. 191PD_PR9 weeks versus 1 year adjuvant trastuzumab for HER2+ early breast cancer: Subgroup analysis of the ShortHER trial allows to identify patients for whom a shorter trastuzumab administration may have a favourable risk/benefit ratio. (23rd October 2018)

Authors:
Conte, P F; Guarneri, V; Bisagni, G; Piacentini, F; Brandes, A A; Cavanna, L; Giotta, F; Aieta, M; Gebbia, V; Frassoldati, A; Musolino, A; Garrone, O; Taverniti, C; Rimanti, A; Sarti, S; Rubino, D; Bologna, A; Vicini, R; Balduzzi, S; D'Amico, R
Journal:
Annals of oncology
Issue:
Volume 29(2018)Supplement 8
Page Start:
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗